Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels

被引:16
|
作者
Lee, Chan Joo [1 ,2 ]
Lee, Yunbeom [3 ]
Park, Sungha [1 ,2 ]
Kang, Seok-Min [1 ,2 ]
Jang, Yangsoo [1 ,2 ]
Lee, Ji Hyun [4 ]
Lee, Sang-Hak [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Div Cardiol,Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea
[3] Kyung Hee Univ, Grad Sch, Dept Med, Seoul, South Korea
[4] Kyung Hee Univ, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
新加坡国家研究基金会;
关键词
APOLIPOPROTEIN-B; GENETIC-VARIANTS; FAMILIAL HYPOBETALIPOPROTEINEMIA; MOLECULAR DIAGNOSIS; HEART-DISEASE; FATTY LIVER; LOW LDL; MUTATIONS; JAPANESE; DYSLIPIDEMIAS;
D O I
10.1371/journal.pone.0186446
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Screening of variants, related to lipid metabolism in patients with extreme cholesterol levels, is a tool used to identify targets affecting cardiovascular outcomes. The aim of this study was to examine the prevalence and characteristics of rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol (LDLC) levels. Methods Among 13,545 participants enrolled in a cardiovascular genome cohort, 22 subjects, whose LDL-C levels without lipid-lowering agents were <= 1 percentile (48 mg/dL) of Korean population, were analyzed. Two target genes, APOB and PCSK9, were sequenced by targeted next-generation sequencing. Prediction of functional effects was conducted using SIFT, PolyPhen-2, and Mutation Taster, and matched against a public database of variants. Results Eight rare variants of the two candidate genes (five in APOB and three in PCSK9) were found in nine subjects. Two subjects had more than two different rare variants of either gene (one subject in APOB and another subject in APOB/PCSK9). Conversely, 12 common variants (nine in APOB and three in PCSK9) were discovered in 21 subjects. Among all variants, six in APOB and three in PCSK9 were novel. Several variants previously reported functional, including c. C277T (p. R93C) and c. G2009A (p. G670E) of PCSK9, were found in our population. Conclusions Rare variants of APOB or PCSK9 were identified in nine of the 22 study patients with extremely low LDL-C levels, whereas most of them had common variants of the two genes.The common novelty of variants suggested polymorphism of the two genes among them. Our results provide rare genetic information associated with this lipid phenotype in East Asian people.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
    Hsu, Lung-An
    Teng, Ming-Sheng
    Wu, Semon
    Chou, Hsin-Hua
    Ko, Yu-Lin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [2] Both Rare and Common Variants in PCSK9 Influence Plasma Low-Density Lipoprotein Cholesterol Level in American Indians
    Tsai, Ching-Wei
    North, Kari E.
    Tin, Adrienne
    Haack, Karin
    Franceschini, Nora
    Voruganti, V. Saroja
    Laston, Sandy
    Zhang, Ying
    Best, Lyle G.
    MacCluer, Jean W.
    Beaty, Terri H.
    Navas-Acien, Ana
    Kao, W. H. Linda
    Howard, Barbara V.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02): : E345 - E349
  • [3] Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
    Honda, Satoshi
    Puri, Rishi
    Anderson, Todd
    Kastelein, John J. P.
    Brennan, Danielle M.
    Kassahun, Helina
    Somaratne, Ransi
    Wasserman, Scott M.
    Nissen, Steve E.
    Nicholls, Stephen J.
    JACC-CARDIOVASCULAR IMAGING, 2022, 15 (04) : 709 - 711
  • [4] PCSK9 gene mutations and low-density lipoprotein cholesterol
    Wu, Na-Qiong
    Li, Jian-Jun
    CLINICA CHIMICA ACTA, 2014, 431 : 148 - 153
  • [5] Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors
    Scherer, Daniel J.
    Nelson, Adam J.
    Psaltis, Peter J.
    Nicholls, Stephen J.
    INTERNAL MEDICINE JOURNAL, 2017, 47 (08) : 856 - 865
  • [6] Low-density lipoprotein cholesterol reduction by inhibition of PCSK9
    Stein, Evan A.
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (06) : 510 - 517
  • [7] A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
    Kotowski, IK
    Pertsemlidis, A
    Luke, A
    Cooper, RS
    Vega, GL
    Cohen, JC
    Hobbs, HH
    AMERICAN JOURNAL OF HUMAN GENETICS, 2006, 78 (03) : 410 - 422
  • [8] Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol Metabolism: Of Mice and Man
    Stein, Evan A.
    Raal, Frederick J.
    CIRCULATION, 2013, 127 (24) : 2372 - 2374
  • [9] Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease
    Dron, Jacqueline S.
    Patel, Aniruddh P.
    Zhang, Yiyi
    Jurgens, Sean J.
    Maamari, Dimitri J.
    Wang, Minxian
    Boerwinkle, Eric
    Morrison, Alanna C.
    de Vries, Paul S.
    Fornage, Myriam
    Hou, Lifang
    Lloyd-Jones, Donald M.
    Psaty, Bruce M.
    Tracy, Russell P.
    Bis, Joshua C.
    Vasan, Ramachandran S.
    Levy, Daniel
    Heard-Costa, Nancy
    Rich, Stephen S.
    Guo, Xiuqing
    Taylor, Kent D.
    Gibbs, Richard A.
    Rotter, Jerome I.
    Willer, Cristen J.
    Oelsner, Elizabeth C.
    Moran, Andrew E.
    Peloso, Gina M.
    Natarajan, Pradeep
    Khera, Amit V.
    JAMA CARDIOLOGY, 2023, 8 (03) : 258 - 267
  • [10] Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
    Mohamed, Farzahna
    Mansfield, Brett
    Raal, Frederick J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)